SCHEMBL21816865

SCHEMBL21816865

O=[N+]([O-])c1ccc(OCCl)c2ncccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.58
ALDH1A1 P00352 10/20 0.58
KMT2A Q03164 6/20 0.58
MEN1 O00255 5/20 0.58
KDM4E B2RXH2 5/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
CTSB P07858 4/20 0.58
LMNA P02545 3/20 0.58
TDP1 Q9NUW8 3/20 0.58
HTT P42858 3/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
HSP90AA1 P07900 2/20 0.58
OPRK1 P41145 2/20 0.58
BRD4 O60885 1/20 0.58
CHRM1 P11229 1/20 0.58
DRD2 P14416 1/20 0.58
ALOX12 P18054 1/20 0.58
ADRA2B P18089 1/20 0.58
ADRA2C P18825 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21816800 0.87 MAPT (0.60) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL23715389 0.83 KMT2A (0.59) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL10915347 0.82 MAPT (0.61) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL9976072 0.82 MEN1 (0.66) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL21816812 0.82 MAPT (0.61) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL27853335 0.82 MAPT (0.55) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL16879230 0.82 KMT2A (0.60) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL9545607 0.82 MAPT (0.58) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL28449760 0.82 MAPT (0.57) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL23715706 0.81 MAPT (0.53) MAPTALDH1A1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152048-B2 Nitroxoline prodrug and use thereof JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-11-26 US disclosed
CN-115697970-B Preparation method of aromatic ether compound 江苏亚虹医药科技股份有限公司 2024-11-15 CN disclosed
CN-115427397-B Crystal form of nitroquinoline prodrug, pharmaceutical composition containing crystal form, preparation method and application of pharmaceutical composition 江苏亚虹医药科技股份有限公司 2024-01-26 CN disclosed
US-20230219928-A1 PREPARATION METHOD FOR AROMATIC ETHER COMPOUND ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) 2023-07-13 US disclosed
US-20230219928-A1 PREPARATION METHOD FOR AROMATIC ETHER COMPOUND ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) 2023-07-13 US disclosed
US-20230219928-A1 PREPARATION METHOD FOR AROMATIC ETHER COMPOUND ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) 2023-07-13 US disclosed
EP-4177243-A1 PREPARATION METHOD FOR AROMATIC ETHER COMPOUND Jiangsu Yahong Meditech Co., Ltd. (CN) 2023-05-10 EP disclosed
EP-4177243-A1 PREPARATION METHOD FOR AROMATIC ETHER COMPOUND Jiangsu Yahong Meditech Co., Ltd. (CN) 2023-05-10 EP disclosed
CN-115697970-A Process for producing aromatic ether compound 江苏亚虹医药科技股份有限公司 2023-02-03 CN disclosed
CN-115427397-A Crystal form of nitroxoline prodrug, pharmaceutical composition containing nitroxoline prodrug, and preparation method and application of nitroxoline prodrug 江苏亚虹医药科技股份有限公司 2022-12-02 CN disclosed
WO-2021258979-A1 PREPARATION METHOD FOR AROMATIC ETHER COMPOUND 江苏亚虹医药科技股份有限公司 2021-12-30 WO disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 US disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 EP disclosed
CN-111295372-B Nitroxoline prodrugs and uses thereof 江苏亚虹医药科技股份有限公司 2021-03-09 CN disclosed
CN-111646936-A Process for producing aromatic ether compound 江苏亚虹医药科技有限公司 2020-09-11 CN disclosed
CN-111295372-A Nitroxoline prodrugs and uses thereof 江苏亚虹医药科技有限公司 2020-06-16 CN disclosed
WO-2020063824-A1 NITROXOLINE PRODRUG AND USE THEREOF 江苏亚虹医药科技有限公司 2020-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152048-B2 Nitroxoline prodrug and use thereof NOS1, NOS2, NNT MAPT 2243/4885ALDH1A1 706/4885KMT2A 2016/4885
US-20230219928-A1 PREPARATION METHOD FOR AROMATIC ETHER COMPOUND F7, F5, CYP2F1 MAPT 2697/4885ALDH1A1 883/4885KMT2A 1035/4885
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF NOS1, NOS2, NNT MAPT 2243/4885ALDH1A1 706/4885KMT2A 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.